Extended interval dosing of natalizumab: is efficacy preserved?

被引：0

作者：

Clerico, M. ^{[1
]}

Signori, A. ^{[2
]}

De Mercanti, S. ^{[1
]}

Cordioli, C. ^{[3
]}

Signoriello, E. ^{[4
]}

Lus, G. ^{[4
]}

Maniscalco, G. T. ^{[5
,6
]}

Curti, E. ^{[7
]}

Lorefice, L. ^{[8
]}

Cocco, E. ^{[8
]}

Nociti, V. ^{[9
]}

Mirabella, M. ^{[9
]}

Baroncini, D. ^{[10
]}

Landi, D. ^{[11
]}

Mataluni, G. ^{[11
]}

Petruzzo, M. ^{[12
]}

Lanzillo, R. ^{[12
]}

Gandoglia, I. ^{[13
]}

Laroni, A. ^{[13
]}

Frangiamore, R. ^{[14
]}

Sartori, A. ^{[15
]}

Cavalla, P. ^{[16
]}

Costantini, G. ^{[16
]}

Sormani, M. P. ^{[2
]}

Capra, R. ^{[3
]}

机构：

[1] Univ Torino, San Luigi Gonzaga Hosp, Neurol Unit, Clin & Biol Sci Dept, Orbassano, Italy

[2] Univ Genoa, Sect Biostat, Dept Hlth Sci, Genoa, Italy

[3] Spedali Civili Brescia, Multiple Sclerosis Ctr, Presidio Montichiari, Brescia, Italy

[4] Univ Naples 2, Dept Med Surg Neurol Metab & Aging Sci, Naples, Italy

[5] AORN A Cardarelli, Neurol Clin, Naples, Italy

[6] AORN A Cardarelli, Multiple Sclerosis Ctr, Naples, Italy

[7] Univ Parma, Dept Med & Surg, Neurol Associates Unit, Parma, Italy

[8] Univ Cagliari, Binaghi Hosp, Dept Med Sci & Publ Hlth, Multiple Sclerosis Ctr, Cagliari, Italy

[9] Fdn Policlin Univ Gemelli, Neurosci Area, Neurosci Aging Head & Neck & Orthopaed Sci Dept, Multiple Sclerosis Ctr, Rome, Italy

[10] ASST Valle Olona, Presidio Osped Gallarate, Ctr Sclerosi Multipla, Gallarate, Italy

[11] Policlin Tor Vergata, UOSD Ctr Riferimento Reg Sclerosi Multipla, Dipartimento Neurosci, Rome, Italy

[12] Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, Multiple Sclerosis Ctr, Naples, Italy

[13] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy

[14] IRCCS Fdn, Dept Neuroimmunol & Neuromuscular Dis, Neurol Inst C Besta, Milan, Italy

[15] Azienda Osped Univ Osped Riuniti, Azienda Sanit Univ Integrata Clin Neurol, Neurol Unit, Trieste, Italy

[16] Torino Univ Hosp, Dept Neurosci, Citta Salute & Sci, Turin, Italy

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P587

引用

页码：282 / 283

页数：2

共 50 条

[41] Natalizumab extended interval dosing: what about wearing-off effect?
Bernardes, Catarina
Fernandes, Catarina
Cunha, Carolina
Nunes, Carla
Macario, Carmo
Sousa, Livia
Batista, Sonia
Correia, Ines
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2024, 458
[42] Progressive Multifocal Leukoencephalopathy with Natalizumab Extended or Standard Interval Dosing in US and ROW
Dsilva, L.
McCarthy, K.
Lyons, J.
Cabigas, B.
Campbell, N.
Kong, G.
Chin, W.
Adams, B.
Kuhelj, R.
Singhal, P.
Smirnakis, K.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 459 - 459
[43] MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study
De Mercanti, Stefania Federica
Signori, Alessio
Cordioli, Cinzia
Signoriello, Elisabetta
Lus, Giacomo
Bonavita, Simona
Abbadessa, Gianmarco
Lavorgna, Luigi
Maniscalco, Giorgia Teresa
Curti, Erica
Lorefice, Lorena
Cocco, Eleonora
Nociti, Viviana
Mirabella, Massimiliano
Baroncini, Damiano
Mataluni, Giorgia
Landi, Doriana
Petruzzo, Martina
Lanzillo, Roberta
Gandoglia, Ilaria
Laroni, Alice
Frangiamore, Rita
Sartori, Arianna
Cavalla, Paola
Costantini, Gianfranco
Capra, Ruggero
Sormani, Maria Pia
Clerico, Marinella
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 424
[44] Long-term effectiveness of extended interval dosing of natalizumab in multiple sclerosis
Ryerson, L. Zhovtis
Lee, S.
Bacon, T.
Toth, E.
Chinea, R.
Gragui, D.
Kister, I.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 358 - 359
[45] Influence of personalized extended interval dosing on the natalizumab wearing-off effect
Toorop, Alyssa
Wessels, Mark
Gelissen, Liza
Hoitsma, E.
Zeinstra, Esther
van Rooij, Luuk
van Munster, Caspar
Vennegoor, Anke
Mostert, Jop
Wokke, Beatrijs
Kalkers, Nynke. F.
Hoogervorst, E. L. J.
van Eijk, Jeroen
Roosendaal, Christiaan
Kragt, Jolijn
Eurelings, Marijke
van Genugten, Jessie
Nielsen, Jessica
Sinnige, Okke
Kloosterziel, Mark
Arnoldus, Edo P. J.
van Dijk, Gert
Bouvy, Willem
Strijbis, Eva
van Oosten, Bob
Brigit, de Jong
Lissenberg-Witte, Birgit
Rispens, Theo
Uitdehaag, Bernard
Killestein, Joep
van Kempen, Zoe
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 387 - 388
[46] Personalized extended interval dosing of natalizumab in multiple sclerosis: a prospective multicenter trial
van Kempen, Z.
Hoogervorst, E.
Kalkers, N.
Mostert, J.
Lissenberg-Witte, B.
de Vries, A.
ten Brinke, A.
van Oosten, B.
Barkhof, F.
Wattjes, M.
Teunissen, C.
Uitdehaag, B.
Rispens, T.
Killestein, J.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 735 - 736
[47] One year of natalizumab extended interval dosing: what have we learned
Bernardes, C.
Fernandes, C.
Correia, I.
Nunes, C.
Macario, C.
Batista, S.
Sousa, L.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 652 - 652
[48] Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
Juliette Pelle
Anais R. Briant
Pierre Branger
Nathalie Derache
Charlotte Arnaud
Christine Lebrun-Frenay
Mikael Cohen
Lydiane Mondot
Jerome De Seze
Kevin Bigaut
Nicolas Collongues
Laurent Kremer
Damien Ricard
Flavie Bompaire
Charlotte Ohlmann
Magali Sallansonnet-Froment
Jonathan Ciron
Damien Biotti
Beatrice Pignolet
Jean-Jacques Parienti
Gilles Defer
Neurology and Therapy, 2023, 12 : 529 - 542
[49] Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis
Moccia, Marcello
Loperto, Ilaria
Santoni, Laura
Masera, Silvia
Affinito, Giuseppina
Carotenuto, Antonio
Lanzillo, Roberta
Triassi, Maria
Morra, Vincenzo Brescia
Palladino, Raffaele
NEURODEGENERATIVE DISEASE MANAGEMENT, 2022, 12 (03) : 109 - 116
[50] Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
Pelle, Juliette
Briant, Anais R.
Branger, Pierre
Derache, Nathalie
Arnaud, Charlotte
Lebrun-Frenay, Christine
Cohen, Mikael
Mondot, Lydiane
De Seze, Jerome
Bigaut, Kevin
Collongues, Nicolas
Kremer, Laurent
Ricard, Damien
Bompaire, Flavie
Ohlmann, Charlotte
Sallansonnet-Froment, Magali
Ciron, Jonathan
Biotti, Damien
Pignolet, Beatrice
Parienti, Jean-Jacques
Defer, Gilles
NEUROLOGY AND THERAPY, 2023, 12 (02) : 529 - 542

← 1 2 3 4 5 →